Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510170 | 0.80 | TDP1 (0.56) | ALDH1A1KDM4EL3MBTL1TDP1PDE3B | |
| SCHEMBL2498171 | 0.79 | NOTUM (0.47) | ALDH1A1KDM4EL3MBTL1TDP1PDE3B | |
| SCHEMBL2376569 | 0.77 | GPR55 (0.52) | ALDH1A1KDM4ETDP1MAPTNPSR1 | |
| SCHEMBL2500703 | 0.76 | ALDH1A1 (0.60) | ALDH1A1KDM4EL3MBTL1PDE3BPDE3A | |
| SCHEMBL2504899 | 0.75 | MEN1 (0.50) | ALDH1A1KDM4EL3MBTL1TDP1HPGD | |
| SCHEMBL2502315 | 0.73 | MAP2K4 (0.49) | ALDH1A1KDM4EHPGDMAPTGFER | |
| SCHEMBL2513299 | 0.73 | MEN1 (0.62) | ALDH1A1KDM4ETDP1HPGDMAPT | |
| SCHEMBL10815770 | 0.72 | PDE5A (0.53) | ALDH1A1KDM4EL3MBTL1PDE3BPDE3A | |
| SCHEMBL12763646 | 0.71 | ALDH1A1 (0.46) | ALDH1A1KDM4EL3MBTL1GRM2TDP1 | |
| SCHEMBL778770 | 0.71 | LMNA (0.50) | GRM2BACE1HPGDMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190248749-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10138210-B2 | Substituted pyridazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170057931-A1 | Substituted pyridazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-2370413-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150191454-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2015-07-09 | — | — | US | disclosed |
| US-8940891-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2370413-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010077275-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | PTGIR, PTGIS, TBXA2R | ALDH1A1 652/4885KDM4E 4766/4885L3MBTL1 4825/4885 |
| US-10138210-B2 | Substituted pyridazines as prostacyclin receptor modulators | PTGIR, PTGIS, PTGER1 | ALDH1A1 683/4885KDM4E 4664/4885L3MBTL1 4858/4885 |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 704/4885KDM4E 4845/4885L3MBTL1 4830/4885 |
| US-20170057931-A1 | Substituted pyridazines as prostacyclin receptor modulators | PTGIR, PTGIS, PTGER1 | ALDH1A1 683/4885KDM4E 4664/4885L3MBTL1 4858/4885 |
| US-20190248749-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 705/4885KDM4E 4845/4885L3MBTL1 4830/4885 |
| US-20150191454-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 704/4885KDM4E 4845/4885L3MBTL1 4830/4885 |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | PTGIR, PTGIS, TBXA2R | ALDH1A1 652/4885KDM4E 4766/4885L3MBTL1 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.